IRF3 and neoplasm: Both poly-I:C and rintatolimod activate TLR3-mediated nuclear translocation of TRAF3 and IRF3, leading to type-1 interferon production and CXCL10 expression, which attract CD8+ T cells for anti-tumor immunity.